CBD Gummies for Autism Symptoms – Clinical Insights
CBD gummies autism symptoms are gaining notable clinical interest as families seek cannabis-based interventions. This emerging research highlights the need for evidence-based guidance. Clinicians must carefully evaluate study quality and safety before…
Cannabinoids for GLP-1 Nausea: CED Clinic Registry Observations in Patients on Semaglutide and Tirzepatide
Nausea is one of the most common reasons people struggle with GLP-1 medications such as semaglutide and tirzepatide. This page summarizes CED Clinic registry observations on cannabinoids for GLP-1 nausea and is clear about what those observations can and…
Cannabinoids & Statins & Lipid-Lowering Agents: Evidence, Pharmacokinetics & Safety Review
Pharmacology & Safety Series Clinically Audited: October 2026 Cannabinoids & Statins & Lipid-Lowering Agents: Evidence, Pharmacokinetics & Safety Review Author & Reviewer: Benjamin Caplan, MD • Family Medicine &…
Cannabinoid Hyperemesis Syndrome (CHS): Concentrates, Hot Water Relief & Absolute Cessation Criteria
Oxford CEBM Evidence Level 1A: Clinical Safety & Non-Efficacy Evaluation CED Clinic Medical Counter-Perspective • Evidence-Based Safety Guardrails Direct Clinical Answer & Safety Consensus Cannabinoid Hyperemesis Syndrome (CHS) is an…
CBD Gummies for Lung Issues: What the Evidence Shows and How They Fit Into Daily Wellness
Patients often inquire about cbd gummies lung issues evidence, but current clinical data is limited. Understanding what the evidence shows is crucial for safe use. This article reviews the scientific findings and their implications for daily wellness.
Real-World Evidence: Sleep Latency, Nocturnal Awakenings & Minor Cannabinoids (CBN/CBG) across 24,000+ Visits
CED Clinic Clinical Registry Real-World Evidence (RWE) CEBM Level 2B: Clinical Registry Cohort Published: October 16, 2026 Real-World Evidence: Sleep Latency, Nocturnal Awakenings & Minor Cannabinoids (CBN/CBG) across 24,000+ Visits Longitudinal…
CBD and SSRI Interactions: What the Evidence Shows for Antidepressants and Cannabis
CBD can change how the body clears certain antidepressants, and the clearest evidence involves citalopram and escitalopram. This review of CBD and SSRI interactions summarizes the laboratory and clinical pharmacokinetic studies, explains why dose timing…
CBD Gummies and Psychosis: What the Evidence Shows for Everyday Use
CBD gummies and psychosis risk remain an area with limited and contradictory evidence. Clinicians must assess psychosis risk carefully when counseling patients using CBD gummies. Understanding the clinical evidence on CBD gummies and psychosis risk is…
Does CBD Gummies Make You Sleepy? What the Evidence and Experience Actually Show
CBD gummies sleep effects vary depending on dose and ingredients. Evidence shows that typical CBD gummy doses may promote alertness rather than sedation. Experience suggests added ingredients often contribute to sleepiness more than CBD itself.
Low-Dose CBD and Therapeutic Value: What the New Clinical Pharmacology Review Found
A review in the British Journal of Clinical Pharmacology evaluated the pharmacokinetics, efficacy, and safety of low-dose cannabidiol. Dr. Caplan reviews this low dose CBD pharmacokinetics safety research and what it adds beyond behavioral-effect…
